OR51E2 and prostate carcinoma: Although this is the first study on OR51J1, studies on OR51E2, another member of this family, which is expressed in melanoma [26] and prostate cancer [27] revealed that its activation via its ligand, β-ionone, inhibits cancer cell proliferation.